The Venture Codex Logo

The Venture Codex

Ribocure Pharmaceuticals

Vetenskapens gränd 11, Mölndal, Vastra Gotaland, 431 53, Sweden

Overview

InnoRNA is a Chinese biotech startup. The company closed a $120 million Series B financing. The round was led by CDH Investments and China Renaissance’s Huaxing Healthcare Capital. The article identifies CDH as an alternative asset manager and Huaxing as Huaxing Healthcare Capital. The article does not disclose the company’s products, operating metrics, use of proceeds, or future plans.

Total raised
$120M
Funding rounds
1
Latest round
Series B
Latest activity
Mar 2022

Industries

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
Visit website

Recent funding

  1. Series B

    Mar 2022

    $120M

Team

  • Li-Ming Gan

    CEO & Co-Founder

    LinkedIn
  • Anders Waas

    Avtalsspecialist

    LinkedIn
  • Kristina Welinder

    Associate Director Clinical Operations

    LinkedIn
  • John Taylor

    Global Head of Business Development

    LinkedIn